Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efavirenz dose-reduction cohort study in children and adolescents with HIV
ChiCTR1900024605Phase 4Not yet recruiting
- Sponsor
- Beijing Ditan Hospital
- Start
- Aug 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of efavirenz in human immunodeficiency virus infection (HIV) (2 arms), sponsored by Beijing Ditan Hospital. Primary endpoints: HIV-RNA, CD4 T-cell count and 3 more. Planned start Aug 2019; status: not yet recruiting.
02
Drugs
efavirenz
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on ChiCTR1900024605.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900024605.